ZFIN Fish: s705Tg

ZFIN ID: ZDB-FISH-161027-2

ZFIN ID: ZDB-FISH-161027-2

Fish name:	s705Tg
Genotype:	s705Tg
Targeting Reagent:	none

HUMAN DISEASE MODELED by s705Tg
No data available

GENE EXPRESSION
Gene expression in s705Tg

RNA expression

Expressed Gene	Structure	Conditions	Figures
amotl2b	liver	standard conditions	Fig. 2 from Cox et al., 2016
atic	whole organism	control	Fig. S4 from Weger et al., 2018
ccn2a	liver	standard conditions	Fig. 2 from Cox et al., 2016
ccn1l2	liver	standard conditions	Fig. 2 from Cox et al., 2016
glula	liver	standard conditions	Fig. 2 from Cox et al., 2016
glulb	liver	standard conditions	Fig. 2 from Cox et al., 2016
paics	whole organism	control	Fig. S4 from Weger et al., 2018
slc2a1a	liver	standard conditions	Fig. 4 from Cox et al., 2018
slc2a2	liver	standard conditions	Fig. 4 from Cox et al., 2018

Protein expression

Antibody	Structure	Conditions	Figures
Ab11-akt	liver	control	Fig. 6 from Cox et al., 2016
Ab9-rps6	liver	control	Fig. 6 from Cox et al., 2016
Ab11-akt	liver	chemical treatment: sirolimus	Fig. 6 from Cox et al., 2016
Ab9-rps6	liver	chemical treatment: sirolimus	Fig. 6 from Cox et al., 2016
Ab5-akt	liver	chemical treatment: sirolimus	Fig. 6 from Cox et al., 2016
Ab5-rps6	liver	control	Fig. 6 from Cox et al., 2016
Ab6-pcna	liver	control	Fig. 7 from Cox et al., 2016
Ab5-akt	liver	control	Fig. 6 from Cox et al., 2016
Ab5-rps6	liver	chemical treatment: sirolimus	Fig. 6 from Cox et al., 2016
Ab6-pcna	liver	chemical treatment: methionine sulfoximine	Fig. 7 from Cox et al., 2016

Reporter gene expression No data available

PHENOTYPE
Phenotype in s705Tg

Phenotype	Conditions	Figures
liver ab5-akt labeling decreased amount, abnormal	chemical treatment: sirolimus	Fig. 6 from Cox et al., 2016
liver ab9-rps6 labeling decreased amount, abnormal	chemical treatment: sirolimus	Fig. 6 from Cox et al., 2016
liver ab5-akt labeling increased amount, abnormal	chemical treatment: methionine sulfoximine	Fig. 6 from Cox et al., 2016
liver slc2a2 expression increased amount, abnormal	standard conditions	Fig. 4 from Cox et al., 2018
liver ab9-rps6 labeling increased amount, abnormal	chemical treatment: methionine sulfoximine	Fig. 6 from Cox et al., 2016
liver glulb expression increased amount, abnormal	standard conditions	Fig. 2 from Cox et al., 2016
liver ccn1l2 expression increased amount, abnormal	standard conditions	Fig. 2 from Cox et al., 2016
liver slc2a1a expression increased amount, abnormal	standard conditions	Fig. 4 from Cox et al., 2018
liver amotl2b expression increased amount, abnormal	standard conditions	Fig. 2 from Cox et al., 2016
liver ccn2a expression increased amount, abnormal	standard conditions	Fig. 2 from Cox et al., 2016
liver glula expression increased amount, abnormal	standard conditions	Fig. 2 from Cox et al., 2016
liver increased mass, abnormal	control	Fig. 7 from Cox et al., 2016
liver size, ameliorated	chemical treatment: methionine sulfoximine	Fig. 7 from Cox et al., 2016
liver cell population proliferation increased occurrence, abnormal	control	Fig. 7 from Cox et al., 2016
liver cell population proliferation occurrence, ameliorated	chemical treatment: methionine sulfoximine	Fig. 7 from Cox et al., 2016
liver glutamate-ammonia ligase activity increased occurrence, abnormal	standard conditions	Fig. 4, Fig. 7 from Cox et al., 2016
liver glutamate-ammonia ligase activity occurrence, ameliorated	chemical treatment: methionine sulfoximine	Fig. 7 from Cox et al., 2016
liver nucleotide biosynthetic process increased occurrence, abnormal	control	Fig. 7 from Cox et al., 2016
liver nucleotide biosynthetic process occurrence, ameliorated	chemical treatment: methionine sulfoximine	Fig. 7 from Cox et al., 2016
whole organism paics expression decreased amount, abnormal	control	Fig. S4 from Weger et al., 2018

CITATIONS (3)